RxDoctor Payments Data

Charlotte Carlson

Medical · Los Angeles, CANPI 1598056426

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,855 of the $29,804 with a category attached, or 63.3%. Amgen accounts for 67.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $10,341 and has fallen 78.3% since, to $2,243 in 2025. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,804in general payments, 2019–2025

Across 490 payments — averaging $60.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$20K
  • Sanofi$2K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • Pfizer$703
  • Sun Pharmaceutical Industries Inc.$610
  • plus $4K from 21 others

What the payments were for

  • Speaking & faculty fees$18,85563%
  • Food & beverage$10,56935%
  • Education$3801%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,804 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$8,662
Medicare patients
49
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab11$45,679
Pimecrolimus19$2,995
Clobetasol Propionate61$2,777
Fluocinonide56$2,350
CiclopiroxCiclopirox Olamine102$2,089
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc101$1,817
Fluorouracil25$1,803
Doxycycline Hyclate102$1,753
Mupirocin229$1,638
Ketoconazole92$1,616
Clindamycin Phosphate26$1,161
ValacyclovirValacyclovir Hcl33$1,089
Fluocinolone Acetonide24$893
Tacrolimus12$600
Fluticasone Propionate24$492

Paid to pharmacies, not to this prescriber.

Other medical in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →